natgillin/translations-raw huggingface dataset:
The following morning (25.25 hr), MTBE (450mL) was added and the reaction mixture was filtered through a pad of silica gel, washed with MTBE followed by EtOAc, and concentrated to give 61.8g oil. 
Sljedećeg jutra (25.25 sati) bio je dodan MTBE (450 mL) i reakcijska smjesa je bila filtrirana kroz filtar silikagela, isprana s MTBE i nakon toga s EtOAc i koncentrirana da bi dala 61.8 g ulja.
a station (40) for longitudinally cutting said advanced sheet (4) into strips (41), 
postaju (40), za uzdužno rezanje navedenog lista pomaknutog prema naprijed (4) u trake (41), -
In a preferred embodiment of the invention, the labeled compound is introduced into a patient in a detectable quantity and after sufficient time has passed for the compound to become associated with amyloid deposits, the labeled compound is detected noninvasively inside the patient. 
Postupak vizualizacije amiloidnih naslaga, naznačen time što se sastoji u: a. unošenju u sisavca detektabilne količine dijagnostičkog pripravka u skladu s patentnim zahtjevom 7; b. ostavljanju dovoljno vremena da se obilježeni spoj veže s amiloidnim naslagama; i c. < detektiranju obilježenig spoja vezanog na jednu ili više amiloidnih naslaga.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having 1 to 20 carbon atoms in the chain. 
"Alk1l" znači alifatska ugljikovodična skupina, koja može biti nerazgranata ili razgranata, s 1 do 20 ugljikovih atoma u lancu.
The symbols are demapped in accordance with the symbol mapping method to output bit streams (S425) 
Simboli su demapirani u skladu sa metodom simbola mapiranja i damapirani tok i usluge je izlazni
In certain embodiments, the paper product coated with a coating comprising a co-processed microfibrillated cellulose and inorganic particulate material composition may have a tear strength about 5% greater, about 10% greater, or about 20% greater than a tear strength of the paper product coated with a coating devoid of a co-processed microfibrillated cellulose and inorganic particulate material composition. 
prvu vlačnu čvrstoću veću od druge vlačne čvrstoće papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili b. prvu čvrstoću na kidanje veću od druge čvrstoće na kidanje papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili
Compound according to claim 1, selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, izabran iz skupine koja se sastoji od:
In interesting embodiments of the present invention more than one amino acid residue located outside the Gla domain is altered, e.g. the alteration embraces removal as well as introduction of amino acid residues comprising an attachment group for the non-polypeptide moiety of choice. 
Varijanta iz bilo kojeg prethodnog zahtjeva, naznačena time, da je najmanje jedan amino kiselinski ostatak koji sadrži vezujuću skupinu za ne-polipeptidni udio bio uveden u položaj smješten izvan Gla domene.
G1A is selected from the group consisting of and R5A; 
G"* je odabran iz skupine koju čine
c purifying the salt of the compound of formula (V) by crystallization in the presence of an acid to form the neutral form of the compound of formula (V). 
Cc) - pročišćavanje soli spoja s formulom (V), kristalizacijom soli spoja s formulom (V) u organskom otapalu ili smjesi organskog otapala i vode u prisutnosti kiseline, da se dobije neutralni oblik spoja s formulom (V).
The pharmaceutical composition for use according to claim 19, characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis. 
Farmaceutski pripravak za uporabu sukladno zahtjevu 19, karakteriziran time što je osteoporoza postmenopauzalna osteoporoza, staračka osteoporoza, sekundarna osteoporoza uzrokovana uporabom terapeutika kao što su steroidi ili imunosupresivi, ili osteoporoza koja prati reumatoidni artritis.
99% * Determined by HPLC analysis The following are non-limiting examples of other acids that can be used to form pharmaceutically acceptable salts of the disclosed inhibitors: acetate, citrate, maleate, succinate, lactate, glycolate, tartrate, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, propionate, butyrate, pyruvate, oxalate, malonate, fumarate, and the like. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
The even more preferred compounds of the formula I or Ia are the compounds of the Examples 1 to 29, especially of the Examples 1 to 28. 
Još veću prednost imaju spojevi formule I ili Ia koji su opisani u primjerima 1 do 29, posebno u primjerima 1 do 28.
The solid oral extended release pharmaceutical dosage form of claim 8, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku za oralnu upotrebu prema zahtjevu 6, naznačen time da je formulacija matrice s produljenim otpuštanjem bila uskladištena pri 40°C i 75% relativne vlažnosti zraka (RH).
In another embodiment, the present invention provides the pharmaceutical formulation provided herein for use in a method for improving cognition or treating cognitive loss in a subject comprising administering to a subject the pharmaceutical formulation comprising crystalline Form II. 
Farmaceutski sastav, sadrži: terapijski učinkovitu količinu kristalnog oblika iz patentnog zahtjeva 1 ili 2. Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi liječenja kognitivnog gubitka kod subjekta koji pati od Alzheimerove bolesti.
The mixture was allowed to cool with agitation. 
Smjesa se ostavi ohladiti uz mućkanje.
The technical veneer that was obtained according to said modification, concerning the aesthetics, were similar to a plate being glued in layers from different materials. 
Tehnički furnir koji je dobiven u skladu s navedenom modifikacijom i što se tiče estetskog izgleda, bio je sličan ploči koja je bila zalijepljena sa slojevima od različitih materijala.
The formulation for parenteral administration according to claim 14, wherein the pharmaceutically acceptable reconstitution solution is selected from the group consisting of distilled water, sterile water, physiologic saline, and bacteriostatic water. 
Formulacija za parenteralnu primjenu prema zahtjevu 15 pri čemu se farmaceutski prihvatljiva rekonstituirana otopina odabire iz grupe koja se sastoji od destilirane ili sterilne vode obično korištene za injekcije, fiziološke otopine ili bakteriostatsku vodu.
When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid;salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid. 
Kada je prisutna bazična skupina, primjeri uključuju soli s mineralnim kiselinama, poput klorovodične, bromovodične, sumporne, dušične, te fosforne kiseline; soli s organskim kiselinama, poput metansulfonske, benzensulfonske, ptoluensulfonske, octene, propionske, vinske, fumarne, maleinske, jabučne, oksalne, jantarne, limunske, benzojeve, bademove, cimetne, mliječne, glikolne, glukuronske, askorbinske, nikotinske, te salicilne kiseline; ili soli s kiselim aminokiselinama, poput asparaginske 1 glutaminske kiseline.
The retroviral vector of claim 3 or 4, wherein the vector comprises sequences, optionally LTR sequences, from at least two different retroviruses, and optionally further wherein the at least two different retroviruses include a lentivirus and/or at least one of the sequences encodes a cis element that provides for cross-packaging of the vector in a viral particle, optionally wherein the cis element is selected from the group consisting of an RRE, an Env gene fragment from the region flanking an RRE, and a cPPT. 
Retrovirusni vektor prema patentnom zahtjevu 3 ili 4, naznačen time što vektor sadrži sekvence, izborno LTR sekvence, iz najmanje dva različita retrovirusa, 1 izborno gdje dodatno najmanje dva različita retrovirusa uključuju lentivirus i/ili najmanje jednu od sekvenci koje kodiraju cis element koji osigurava unakrsno pakiranje vektora u virusnu česticu, gdje je izborno cis element odabran iz grupe koja se sastoji od RRE, fragmenta Env gena iz područja koji omeđuje RRE, i cPPT.
a light chain of sequence selected from SEQ ID Nos. 
laki lanac sekvencije odabrane od SEQ ID br.
The method according to claim 1, wherein the compound of general formula (I) is selected from the group consisting of: 8-Hydroxy-N-(thiophen-2-ylmethyl)quinoline-7-carboxamide; 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine: 8-hidroksi-N-(tiofen-2-ilmetil)kinolin-7-karboksamid
wherein HX is an optically active acetylated amino acid of formula (III): wherein: 
(dB) gdje je HX optički aktivna acetilirana aminokiselina formule (III): gdje: nje0,1,2ili3,
Advantageously, the belling machine comprises a stage 64 for cooling the water located along the water feed line 61 . 
Stroj za oblikovanje u zvono prema zahtjevu 3, naznačen time da sadrži fazu hlađenja vode (64) koja je smještena uzduž linije za uvođenje vode (61).
The pharmaceutical composition of claim 4, wherein the orally administrable composition is selected from the group consisting of a tablet, a capsule, a granule, a powder and a syrup. 
Farmaceutski sastav iz patentnog zahtjeva 2, pri čemu je sastav koji se može primjenjivati oralno odabran iz grupe koja se sastoji od tableta, kapsula, granula, praška i sirupa.
spraying a quantity of water of between 5% and 35% by weight with respect to the weight of the said mixture, and introducing air at a temperature below 80°C with a moisture content of less than 5000 ppm, for less than 30 minutes. 
(a) raspršivanjem vode u količini od između 5 težinskih % 1 35 težinskih % u odnosu na težinu spomenute mješavine, 1 (b) uvođenjem zraka temperature ispod 80"C sa sadržajem vlage manjim od 5000 ppm, na manje od 30 minuta.
Certain compounds of formula (1) are capable of existing in stereoisomeric forms. 
HR P20140023 T1 PATENTNI ZAHTJEVI Spoj sa formulom (1) x"
The anti-sclerostin antibody for use in the method of any one of claims 1-9, wherein the anti-sclerostin antibody is an antibody or fragment thereof that demonstrates a binding affinity for sclerostin of SEQ ID NO: 1 of less than or equal to 1 x 10-7 M. 
Antisklerostinsko antitijelo za primjenu u načinu prema bilo kojem zahtjevu od 1 do 9, naznačeno time, što antisklerostinsko antitijelo jest antitijelo ili njegov fragment koji iskazuje afinitet vezivanja za sklerostin od SEQ ID NO: 1 manji ili jednak 1 x 10 "M.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Ra i Rb su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; i RC i Rd su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
It is important to note that both compounds showed equivalent efficacy in a heterotopic rat heart transplant model at the same 2.5 mg/kg/day dose used in this study (Example 12). 
Važno je uočiti da oba spoja pokazuju ekvivalentnu učinkovitost u modelu heterotopične transplantacije srca štakora, u istoj dozi (2,5 mg/kg/dan) kao što je korišteno u ovoj studiji (Primjer 12).
In certain further embodiments the recombinant expression construct is present in a viral vector, such as an adenovirus, adeno-associated virus, herpesvirus, lentivirus, poxvirus or retrovirus vector. 
Pripravak cjepiva u skladu s patentnim zahtjevom 9, naznačen time što se virusni vektor bira iz skupine koju čine adenovirusni vektor, adenoasocirani virusni vektor, herpesvirusni vektor, lentivirusni vektor, poksvirusni vektor 1 retrovirusni vektor.
The composition of claim 1, wherein X1 is halo and m is 5, 6, 7 or 8. 
Sastav prema zahtjevu 1, naznačeno time da je X; halo te mje 5, 6, 7 ili 8.
represents a hydrogen atom, a straight or branched alkyl group, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl group; alkoxy- or alkenyloxy- substituted alkyl; alkylcarbonyl; alkoxycarbonylalkyl; or trifluoromethyl group; 
RiRo su isti_ili različiti, i svaki predstavlja vodik, halogen, hidroksil; ravnu ili razgranatu alkil skupinu, hidroksialkil, haloalkil, alkenil, ili alkinil skupinu; ravnu ili razgranatu alkoksil skupinu; ili ravnu ili razgranatu tioalkil skupinu;
Thus the dispensing tube can be connected to a dispensing tap, even when the container is oriented with the outlet facing down, as long as the hollow piercer has not yet pierced the sealed outlet of the container. 
Tako se cijev za točenje može spojiti na pipac za točenje, čak i onda kad je izlaz spremnika usmjeren prema dolje, sve dok šuplje bušilo ne probije začepljen izlaz spremnika.
The method according to claim 4 or 5, wherein: amylase is added to the texturized food product after the extruder cooking step but before the additional high pressure cooking. 
Postupak prema bilo kojem od patentnih zahtjeva 5 do 9, naznačen time što se amilaza dodaje teksturiranom prehrambenom proizvodu nakon koraka kuhanja u ekstruzijskom kuhalu ali prije dodatnog koraka kuhanja pod visokim tlakom.
The method according to claim 1, wherein the disease or disorder is liver cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
a heavy chain having a heavy chain variable region comprising SEQ ID NO: 81, or an antigen-binding fragment thereof, and a light chain having a light chain variable region comprising SEQ ID NO: 82, or an antigen-binding fragment thereof; 
Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da teški lanac obuhvaća varijabilnu regiju i konstantnu regiju, naznačen time da varijabilna regija ima slijed SEQ ID NO: 10.
substituted and unsubstituted heterocyclyl, and 
(e) supstituirani i nesupstituirani heterociklil, i
The assembly 212 is closed in a downward region by an insole 216, which is perforated in this embodiment but can be made of breathable material. 
Sklop 212 je zatvoren u donjem dijelu unutarnjim potplatom 216, koji je u ovom utjelovljenju perforiran, ali može biti izrađen i od prozračnog materijala.
The antibody of claim 1, wherein said antibody comprises the heavy chain variable region of SEQ ID NO:40. 
Antitijelo u skladu sa zahtjevom 1 ili zahtjevom 2, naznačeno time, da navedeno antitijelo sadrži izolirani polipeptid koji sadrži sekvencu teškog lanca varijabilne regije od SEQ ID NO: 40.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 0.40% to 0.45% of a flavoring agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (£/100 ml), otprilike 0,40 % do otprilike 0,45 % sredstva za aromatiziranje.
A soft chewable composition according to claim 1 or claim 2 wherein the binder is selected from polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene glycols, co-polymers of vinyl acetate and vinylpyrrolidone, and starch, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje prema zahtjevu 5, naznačen time, da vezivo je polivinilpirolidon, kopolimer vinilacetata i vinilpirolidona, ili polietilen-glikol, ili njihove kombinacije.
46), wherein Xxx1, Xxx3 and Xxx4 is an amino acid other than Cys, and wherein said cyclic peptide is capable of reducing an antibody-mediated activation of B1-adrenergic receptor (B1-AR); 
46), gdje su Xxx,, XxX3 1 Xxxa aminokiseline koja nisu Cys, i gdje navedeni ciklički peptid i) "može smanjiti protutijelom inducirano aktiviranje B,-adrenergičkog receptora (Bi1-AR);
The process of claim 1, wherein the product stream comprises methane. 
Proces prema patentnom zahtjevu 9, naznačen time, da struja produkta sadrži metan.
Preferably the drug injection device comprises further a sensor adapted to signal the controller when the lid is closed to allow the controller to drive the drug syringe mounting component and the piston. 
Uređaj za injektiranje lijeka prema zahtjevu 1, naznačen time što uređaj za injektiranje lijeka sadrži daljnji senzor prilagođen za signaliziranje upravljačkom uređaju kada je zatvoren poklopac (11) kako bi se omogućilo upravljačkom uređaju da pogoni komponentu za postavljanje štrcaljke za lijek i klip (29).
Film as in claim 5, characterized in that said second layer (210) contains said second mixture (B) in an amount comprised between 20% and 60% in weight of the total weight of said first film (10). 
Film prema zahtjevu 5, naznačen time da navedeni drugi sloj (210) sadrži navedenu drugu mješavinu (B) u količini koja sadrži između 20% 1 60% težinski ukupne težine navedenog prvog filma (10).
Method according to claim 3 wherein the pair of asymmetric keys is 1024 bit. 
Metoda temeljem zahtjeva 1 naznačena time što par asimetričnih ključeva ima 1024 bit-a.
Exemplary polymers include without limitation polyalkylene glycols, polyalkylene oxides, polyacrylic acid, polyacrylates, polyacrylamide or N-alkyl derivatives thereof, polymethacrylic acid, polymethacrylates, polyethylacrylic acid, polyethylacrylates, polyvinylpyrrolidone, poly(vinylalcohol), polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, dextran, chitosan, polyaminoacids. 
Polimerni konjugat iz zahtjeva 1 ili 2, naznačen time, što je polimer linearna ili razgranata polimerna komponenta iz grupe koja se sastoji od polialkilen-glikola, polialkilen-oksida, poliakrilne kiseline, poliakrilata, poliakrilamida ili N-alkil derivata _ toga, polimetakrilne kiseline, polimetakrilata, polietilakrilne kiseline, -polietilakrilata, polivinilpirolidona, poli(vinil-alkohola), poliglikolne kiseline, polilmliječne kiseline, poli (mliječne-ko-glikolne) kiseline, dekstrana, hitozana ili poliamino-kiseline.
The amino acid sequence of an exemplary human and murine Jagged1 and Jagged2 is shown in FIG. 
SEKVENCE: 78; HVR-H2 koji sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR.
and the amount of the oxidation decomposition product present in the composition is not more than 0.5% w/w relative to laquinimod. 
određivanje ukupne količine produkta oksidacijskog raspadanja u uzorku šarže nakon ispitivanja stabilnosti: i
The fuel according to any one of examples 1-7, wherein the renewable fuel oil has a water content in the range of between 10-40 wt.%. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i/ili manje od 0,1 wt. %.
The radioactive metal-labeled anti-p-cadherin antibody of claim 1, wherein the metal-chelating reagent is selected from the group consisting of isothiocyanobenzyl DOTA, methylisothiocyanobenzyl DTPA, and cyclohexylisothiocyanobenzyl DTPA. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je reagens za keliranje metala odabran iz skupine koju čine izotiocijanobenzil DOTA, metilizotiocijanobenzil DTPA i cikloheksilizotiocijanobenzil DTPA.
An energy generator (50) for obtaining energy from a succession of nuclear reactions between hydrogen (31) and a metal, wherein said metal is a transition metal (19), said generator comprising: 
Generator energije (50) za dobivanje energije iz slijeda nuklearnih reakcija između hidrogena (31) i metal, naznačen time da je navedeni metal prijelazni metal (19), 1 da se navedeni generator sastoji od:
The conjugate of any one of claims 2 to 5, wherein the amino acid sequence of the conjugate and the amino acid sequence of the antibody or fragment thereof are not separated by any linker amino acid sequence. 
Imunocitokin u skladu s patentnim zahtjevom 2, naznačen time što aminokiselinski slijed konjugata i aminokiselinski slijed protutijela, ili njegovog fragmenta, nisu razdvojeni aminokiselinskim slijedom bilo koje spojnice.
In a preferred embodiment, the said 2-((1-methylpropyl)amino)ethanol additive is added as a water based solution to the calcium carbonate-comprising material. 
Uporaba u skladu s patentnim zahtjevom 1, karakterizirana na način da je navedeni aditiv 2-((1- metilpropil)amino)etanol dodan kao otopina na bazi vode materijalu koji sadrži kalcijev karbonat.
The composition of claim 1, wherein said composition contains fewer than about 1 contaminating parent bacterial cell per 109 minicells. 
Pripravak prema zahtjevu 1, gdje taj pripravak sadrži manje od oko 1 kontaminirajuće roditeljske bakterijske stanice na 10? mini-stanica.
Also disclosed is, a method for making an antigen-binding protein, comprising exposing a mouse as described herein to an antigen; allowing the mouse to mount an immune response; and obtaining from the mouse an antigen-binding protein that binds the antigen, or obtaining from the mouse a sequence to be employed in making an antigen-binding protein that binds the antigen. 
Postupak za izradu antitijela u mišu koji se sastoji od a) b) izlaganja miša prema bilo kojem zahtjevu od 1 do 10ili 17 antigenu; puštanja miša da razvije imunološki odgovor na antigen; i izoliranja iz miša (b) antitijela koje specifično prepoznaje antigen ili izoliranja iz miša (b) stanice koja se sastoji od imunoglobulinske domene koja posebno prepoznaje antigen, pri čemu antitijelo sadrži lanac dobiven iz humanog VA segmenta gena, humanog JA segmenta gena i mišjeg CK gena.
A process according to claim 4 or 5 wherein X is HN-CH2-CH2-NH2. 
Postupak u skladu sa zahtjevom 4 ili 5, naznačen time, da X je HN-CH,-CH>-NH,.
The polymer matrix layer may optionally include a pharmaceutically acceptable crosslinking agent. 
Sloj polimernog matriksa može opcionalno uključivati farmaceutski prihvatljivo sredstvo za umrežavanje.
Use of any of Claims 56 to 61, wherein the IL-17 antagonist is a bispecific antibody or bispecific antibody fragment that binds to and inhibits the activity of a) IL-17 and IL-23p19; or b) IL-17 and IL-23R. 
Uporaba u skladu s bilo kojim zahtjevom 56 do 61, naznačena time, da IL-17 antagonist je bispecifično antitijelo ili fragment bispecifičnog antitijela koje se veže na i inhibira djelovanje a) IL-17 i 1L-23p19, ili b) IL-1711L-23R.
represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, 
Ry predstavlja atom vodika ili ravnu ili razgrananu (C;-C4) alkilnu skupinu,
The mixture was aged at room temp for 1½ hrs before being cooled in an ice/water bath for 30 min, the mixture was filtered and the cake washed with isooctane (5 ml). 
Smjesa zrije 1 sat na sobnoj temperaturi prije 30 minuta hlađenja u kupelji s ledenom vodom, smjesu se zatim filtrira, a kolač ispere izooktanom (5 ml).
Solution for intravenous administration 
Otopina za intravenozno davanje